Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study

Background: With the increasing disease burden of cancer worldwide, more and more anticancer drugs have been approved in many countries, and the results of budget impact analyses (BIAs) have become important evidence for related reimbursement decisions.Objectives: We systematically reviewed whether...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yue Ma, Yuxin Li, Aixia Ma, Hongchao Li
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	budget impact analysis anticancer drugs economic evaluation reimbursement scope of costs Public aspects of medicine RA1-1270
Acceso en línea:	https://doaj.org/article/2e175a107aee43b9a45db05e75ab7dc0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2e175a107aee43b9a45db05e75ab7dc0
record_format	dspace
spelling	oai:doaj.org-article:2e175a107aee43b9a45db05e75ab7dc02021-11-05T06:06:09ZIs the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study2296-256510.3389/fpubh.2021.777199https://doaj.org/article/2e175a107aee43b9a45db05e75ab7dc02021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fpubh.2021.777199/fullhttps://doaj.org/toc/2296-2565Background: With the increasing disease burden of cancer worldwide, more and more anticancer drugs have been approved in many countries, and the results of budget impact analyses (BIAs) have become important evidence for related reimbursement decisions.Objectives: We systematically reviewed whether BIAs for anticancer drugs consider the scope of costs rationally and compared the results of different cost scopes to provide suggestions for future analyses and decision-making.Methods: Eligible BIAs published in PubMed, Embase, Web of Science, and the Cochrane Library from 2016 to 2021 were identified based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We extracted 15 terms from the included studies and analyzed how they considered the scope of costs. In addition, a budget impact model was developed for the introduction of geptanolimab to China's National Reimbursement Drug List to enable a comparison of two cost-scope scenarios.Results: A total of 29 studies were included in the systematic review. All 29 studies considered the costs of anticancer drugs, and 25 (86%) also considered condition-related costs, but only 11 (38%) considered subsequent treatment costs. In the comparative study, the predicted budget impacts from 2022 to 2024 were significantly impacted by subsequent treatment costs, with annual differences between the two cost-scope scenarios of $39,546,664, $65,866,161, and $86,577,386, respectively.Conclusions: The scope of costs considered in some existing BIAs for anticancer drugs are not rational. The variations between different cost scopes in terms of budget impact were significant. Thus, BIAs for anticancer drugs should consider a rational scope of costs that adheres to BIA guidelines. Researchers and decision-makers should pay more attention to the scope of costs to achieve better-quality BIAs for anticancer drugs and enhance reimbursement decision-making.Yue MaYue MaYuxin LiYuxin LiAixia MaAixia MaHongchao LiHongchao LiFrontiers Media S.A.articlebudget impact analysisanticancer drugseconomic evaluationreimbursementscope of costsPublic aspects of medicineRA1-1270ENFrontiers in Public Health, Vol 9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	budget impact analysis anticancer drugs economic evaluation reimbursement scope of costs Public aspects of medicine RA1-1270
spellingShingle	budget impact analysis anticancer drugs economic evaluation reimbursement scope of costs Public aspects of medicine RA1-1270 Yue Ma Yue Ma Yuxin Li Yuxin Li Aixia Ma Aixia Ma Hongchao Li Hongchao Li Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study
description	Background: With the increasing disease burden of cancer worldwide, more and more anticancer drugs have been approved in many countries, and the results of budget impact analyses (BIAs) have become important evidence for related reimbursement decisions.Objectives: We systematically reviewed whether BIAs for anticancer drugs consider the scope of costs rationally and compared the results of different cost scopes to provide suggestions for future analyses and decision-making.Methods: Eligible BIAs published in PubMed, Embase, Web of Science, and the Cochrane Library from 2016 to 2021 were identified based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We extracted 15 terms from the included studies and analyzed how they considered the scope of costs. In addition, a budget impact model was developed for the introduction of geptanolimab to China's National Reimbursement Drug List to enable a comparison of two cost-scope scenarios.Results: A total of 29 studies were included in the systematic review. All 29 studies considered the costs of anticancer drugs, and 25 (86%) also considered condition-related costs, but only 11 (38%) considered subsequent treatment costs. In the comparative study, the predicted budget impacts from 2022 to 2024 were significantly impacted by subsequent treatment costs, with annual differences between the two cost-scope scenarios of $39,546,664, $65,866,161, and $86,577,386, respectively.Conclusions: The scope of costs considered in some existing BIAs for anticancer drugs are not rational. The variations between different cost scopes in terms of budget impact were significant. Thus, BIAs for anticancer drugs should consider a rational scope of costs that adheres to BIA guidelines. Researchers and decision-makers should pay more attention to the scope of costs to achieve better-quality BIAs for anticancer drugs and enhance reimbursement decision-making.
format	article
author	Yue Ma Yue Ma Yuxin Li Yuxin Li Aixia Ma Aixia Ma Hongchao Li Hongchao Li
author_facet	Yue Ma Yue Ma Yuxin Li Yuxin Li Aixia Ma Aixia Ma Hongchao Li Hongchao Li
author_sort	Yue Ma
title	Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study
title_short	Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study
title_full	Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study
title_fullStr	Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study
title_full_unstemmed	Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study
title_sort	is the scope of costs considered in budget impact analyses for anticancer drugs rational? a systematic review and comparative study
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/2e175a107aee43b9a45db05e75ab7dc0
work_keys_str_mv	AT yuema isthescopeofcostsconsideredinbudgetimpactanalysesforanticancerdrugsrationalasystematicreviewandcomparativestudy AT yuema isthescopeofcostsconsideredinbudgetimpactanalysesforanticancerdrugsrationalasystematicreviewandcomparativestudy AT yuxinli isthescopeofcostsconsideredinbudgetimpactanalysesforanticancerdrugsrationalasystematicreviewandcomparativestudy AT yuxinli isthescopeofcostsconsideredinbudgetimpactanalysesforanticancerdrugsrationalasystematicreviewandcomparativestudy AT aixiama isthescopeofcostsconsideredinbudgetimpactanalysesforanticancerdrugsrationalasystematicreviewandcomparativestudy AT aixiama isthescopeofcostsconsideredinbudgetimpactanalysesforanticancerdrugsrationalasystematicreviewandcomparativestudy AT hongchaoli isthescopeofcostsconsideredinbudgetimpactanalysesforanticancerdrugsrationalasystematicreviewandcomparativestudy AT hongchaoli isthescopeofcostsconsideredinbudgetimpactanalysesforanticancerdrugsrationalasystematicreviewandcomparativestudy
_version_	1718444458823909376

Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study

Ejemplares similares